As outlined in this RFA (RFA-NS-02-010) announcement, the aims of this project are to create a clinical center for the conduct of future clinical trials of neuroprotection for Parkinson's disease. This site has three board-certified neurologists trained in movement disorders who will participate in this proposed project. Upon implementation of this project these neurologists will collaborate to conduct a pilot trial of an agent to prevent disease progression in PD. Subsequently, additional collaboration with the other clinical center sites will lead to at least one multicenter trial. This project will help to maintain a stable infrastructure for the administration of the clinical trial(s) in neuroprotection related to Parkinson's disease. In addition, the conduct of this type of clinical trial(s) will generate a sample of patients with early PD who may be willing to participate in genetic studies. Similarly, subjects may be willing to participate in studies to identify markers from blood or cerebrospinal fluid that may indicate disease presence or severity. This research may lead to a greater understanding of PD and better treatments.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10NS044555-10
Application #
8206531
Study Section
Special Emphasis Panel (ZNS1-SRB-L (01))
Program Officer
Moy, Claudia S
Project Start
2002-09-15
Project End
2012-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
10
Fiscal Year
2012
Total Cost
$41,836
Indirect Cost
$14,581
Name
Vanderbilt University Medical Center
Department
Neurology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
NINDS NET-PD Investigators (2008) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 31:141-50
Elm, Jordan J; Kamp, Cornelia; Tilley, Barbara C et al. (2007) Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord 22:822-7